Health & Bio Technology Summit

The 2014 event attracted a wide cross-section of top innovators from NY’s burgeoning health & bio technology community. Held at the Zuckerman Auditorium @MSKCC, HBTS showcased 25 emerging companies and over 400 attendees – including entrepreneurs and investors (venture, angel and corporate) along with key industry press and the most connected healthcare executives in the NY region.
Thursday, November 6th, 2014
1:00pm

Opening Remarks

  • Maria Gotsch, CEO, Partnership Fund for New York City
  • Eric Gertler, EVP, New York City Economic Development Corporation & Managing Director, Center for Economic Transformation (CET) for the City of New York
1:10

Keynote

Christoph Westphal, M.D. Ph.D., Chairman & CEO, Flex Pharma; co-founder and Partner, Longwood Fund

THERAPEUTICS PRESENTATIONS

1:30

Memorial Sloan Kettering, Sloan Kettering Institute

Eric Pamer, M.D., Laboratory Head, Immunology Program Topic & Technology: Native intestinal bacteria to treat C. difficile infection
1:40

SUNY Downstate Medical Center

M. Mahmood Hussain, Ph.D., Distinguished Professor of Cell Biology Topic & Technology: Novel drug candidate that reduces plasma cholesterol and atherosclerosis Download Presentation Deck
1:50

Memorial Sloan Kettering, Memorial Hospital Research Laboratories

Andres Lopez-Albaitero, M.D., Clinical Fellow, Laboratory of Nai-Kong Cheung, M.D., Ph.D. Topic & Technology: Elimination of targeted therapy resistance in HER2(+) tumors with a novel HER2/CD3 bispecific antibody
2:00

Mount Sinai Innovation Partners

Michael Ohlmeyer, Ph.D., Associate Professor of Structural and Chemical Biology Topic & Technology: Dual Therapeutics is an oncology start-up company developing novel therapeutics for prostrate cancer, lung cancer, and acute lymphoblastic leukemia
2:10

The City University of New York

Probal Banerjee, Ph.D., Professor of Chemistry, Biochemistry and Neuroscience, The College of Staten Island Topic & Technology: Novel Plant Derived Therapeutic for Human Papillomavirus Infection and Associated Cancers Download Presentation Deck
2:20

Cold Spring Harbor Laboratory

Andreas Grill, DepYmed, Inc. Topic & Technology: A joint venture of Cold Spring Harbor Laboratory and Ohr Pharmaceutical, Inc., established to research Trodusquemine and its analogs as cancer therapeutics Download Presentation Deck
2:30

Albert Einstein College of Medicine at Yeshiva University

Jonathan R. Lai, Ph.D., Associate Professor in the Department of Biochemistry at the Albert Einstein College of Medicine Topic & Technology: Synthetic Antibodies for Ebola Virus Immunotherapy Download Presentation Deck
2:40

Columbia University

Konstantin Petrukhin, Ph.D., Associate Professor of Ophthalmology Topic & Technology: RBP4 antagonists for treatment of atrophic age-related macular degeneration Download Presentation Deck

BIG DATA & SAAS

2:50

Stony Brook University

Dr. William Moore, M.D., President, Right Dose, Inc. Topic & Technology: A cloud based system that allows rapid, effective and accurate radiation dose monitoring for hospitals and imaging centers

NETWORKING BREAK

DIAGNOSTICS PRESENTATIONS

3:30

The Rockefeller University

W. Vallen Graham Topic & Technology: Using conformation-specific biologics to detect amyloid disease biomarkers
3:40

SUNY Downstate Medical Center

Allen J. Norin, Ph.D., D(ABHI), Professor,  Medicine & Cell Biology/Director, Transplant Immunology & Immunogenetics Laboratory

Topic & Technology: New streamlined, platform-independent, lymphocyte response diagnostic for clinical laboratories Download Presentation Deck
3:50

Cold Spring Harbor Laboratory

Lolahon Kadiri, M.D., PH.D., Chief Scientific Officer, Certerra, Inc. Topic & Technology: Specialized CRO partnering to develop CNS drugs and identify CNS side effects in other therapeutics
4:00

The Rockefeller University

Michael P. Rout Topic & Technology: Rapid And Low Cost Approach For The Production Of Large Repertoires Of Highly Specific Diagnostic or Therapeutic Nanobodies
4:10

The City University of New York

Laura Motta-Mena, Ph.D., Senior Research Associate, Gardner Lab, Structural Biology Initiative, CUNY Advanced Science Research Center Topic & Technology: Light-controlled system that is nontoxic, noninvasive, and enables users to perform precisely localized and timed gene activation in cultured cells and animals Download Presentation Deck

DEVICES PRESENTATIONS

4:20

Hospital for Special Surgery

Yukiji Fujimoto and Rick Eddy, Annulo Patch Topic & Technology: A thin / strong material that prevents discs from re-herniating Download Presentation Deck
4:30

Hospital for Special Surgery

Tom Cirrito Topic & Technology: Implant to Treat Cartilage Injuries; Non-degradable devices to treat cartilage and bone injuries Download Presentation Deck
4:40

New York University

Frank Minella, COO, Advanced Neural Metrics, Inc. Topic & Technology: Developing a system for the objective and quantitative measurement of pain using electroencephalography Download Presentation Deck
 4:50

Albert Einstein College of Medicine at Yeshiva University

Thomas K Aldrich, M.D., Director of Pulmonary Function Laboratory at Montefiore Medical Center (Moses Division) and Director of the Pulmonary/Critical Care Training Program and Professor in the Department of Medicine at the Albert Einstein College of Medicine Topic & Technology: Pulseless Oximeter - A novel device able to non-invasively and painlessly measure blood oxygen levels when standard pulse oximetry fails​ Download Presentation Deck
 5:00

Stony Brook University

Sharon Barkume Topic & Technology: Ultrasound Imaging for Musculoskeletal Tissue Diagnosis, and Guided Treatment
 5:10

Cornell University

Gang Lin, Ph.D., Assistant Research Professor in the Department of Microbiology and Immunology at Weill Cornell Medical College Topic & Technology: Novel Immunoproteasome inhibitors that reversibly inhibit the immunoproteasome with high selectively over the constitutive proteasome; useful in therapies directed toward autoimmune diseases, inflammation, transplant rejection and certain cancers
 5:20

Cornell University

Dr. William Reisacher, Associate Professor of Otolaryngology and Director, Allergy Center Topic & Technology: Smell Again: consumer device to provide olfactory training to people with lost or diminished sense of smell
 5:30

Mount Sinai Innovation Partners

Michael Palese, M.D., Director of Minimally Invasive Urology & Associate Professor, Urology Topic & Technology: Magnetic needle retrieval device

Closing Remarks

5:40

Cocktails, Hors d'Oeuvres & Networking

cristoph

Christoph Westphal, MD PhD

CEO, Flex Pharma

Flex Pharma CEO and co-founder Dr. Christoph Westphal is a co-founder and Partner of Longwood Fund, which founds and invests in healthcare companies. Dr. Westphal also currently serves as the co-founder, former CEO, and Executive Chairman of Verastem (NASDAQ: VSTM), a Longwood portfolio company. Dr. Westphal co-founded Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), and OvaScience (NASDAQ: OVAS), where he also serves on the Board of Directors. In addition, he co-founded Sirtris in 2004 (NASDAQ: SIRT; acquired by GSK), and served as CEO until 2010. Dr. Westphal previously served as co-founder/CEO of Alnylam Pharmaceuticals (NASDAQ: ALNY), Acceleron Pharmaceuticals (NASDAQ: XLRN) and Momenta Pharmaceuticals (NASDAQ: MNTA). Companies founded by Dr. Westphal have invented important drugs, including the largest-selling heparin in the US, and several experimental medicines: for cystic fibrosis (phase 3), for currently incurable cancers (phase 2), and for serious inflammatory disorders (phase 2). Dr. Westphal serves on the Board of Fellows of Harvard Medical School, and the Board of Overseers of the Boston Symphony Orchestra.

Dr. Westphal holds an M.D. from Harvard Medical School and a Ph.D. in genetics from Harvard University. He graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University.
orin

Orin Herskowitz

VP, Intellectual Property and tech Transfer, Columbia University

Orin Herskowitz is the VP of Intellectual Property and Tech Transfer for Columbia University, as well as Executive Director of Columbia Technology Ventures (CTV). He also is an Adjunct Professor at Columbia’s Business and Engineering Schools. He has served on boards for a number of innovation and entrepreneurship-focused initiatives in NYC, including the NYC Media Lab, the PowerBridgeNY clean energy proof-of-concept center, the Columbia Coulter Translational Partnership, the NYC ACRE technology incubator, and Harlem Biospace; has been a peer reviewer for innovation and entrepreneurship awards for the National Science Foundation and the Association of Public and Land-grant Universities; and is a frequent speaker at technology-focused events in NYC and across the country. Orin received his BA from Yale and his MBA from the Wharton School of Business. Prior to joining Columbia, Orin spent 7 years at the Boston Consulting Group's New York office as a strategy consultant, and was previously an entrepreneur and a consultant to start-ups.

Columbia Technology Ventures is the tech transfer office of Columbia University. Our core objective is to facilitate the transfer of inventions from academic research to outside organizations for the benefit of society on a local, national and global basis. Each year, CTV manages more than 350 invention disclosures from faculty, 100 license deals and 15 new start-ups. CTV currently has over 1200 patent assets available for licensing, across research fields such as bio, IT, cleantech, devices, nanotechnology, and material science. Columbia Technology Ventures has a particular focus on start-up companies. Over the years, CTV has been involved with launching over 180 companies based on Columbia's technologies. Of these companies, over 40 have received VC funding, with over 25 successful acquisitions or IPOs to date. For more information, please visit www.techventures.columbia.eduFor more information, please visit www.techventures.columbia.edu
eric

Eric Gertler

Executive Vice President and Managing Director for the Center for Economic Transformation

Prior to his role at NYCEDC, Eric served in leadership roles at a number of technology companies including Altruik, PrimeAxis Media, and Privista. Prior to these initiatives, Eric worked in the magazine and newspaper industries where he last served as the president of U.S. News & World Report, Fast Company, and The Atlantic Monthly. He is also the author of the Random House book Prying Eyes: Protect Your Privacy From People Who Sell To You, Snoop on You, or Steal From You. He is a graduate of Brown University and obtained his juris doctor from American University, where he served as editor-in-chief of the Law Review.

maria

Maria Gotsch

President & CEO, Partnership Fund for New York City

Maria is the President and CEO at the Partnership Fund for New York City, the investment arm of the Partnership for New York City. In addition to leading the Fund’s investment operations, Maria has spearheaded the creation and operation of a number of the Fund’s strategic initiatives, including: FinTech Innovation Lab; New York Digital Health Accelerator; NYCSeed (seed financing for IT/digital media companies); BioAccelerate Prize NYC (proof-of-concept funding for university-based biomedical research); Arts Entrepreneurial Loan Fund (low cost loans for mid-size arts groups); and ReStart Central and Financial Recovery Fund (assistance and funding for small businesses impacted by 9/11/01).

Prior to joining the Fund in 1999, Maria was a Managing Director at BT Wolfensohn (now part of Deutsche Bank), providing strategic and financial advice related to mergers, acquisitions, dispositions, joint ventures and the development of business strategies. Before starting with Wolfensohn, Maria worked at LaSalle Partners in the New York area and for Merrill Lynch Capital Markets in New York and London. Maria has an MBA from Harvard Business School and a B.A. from Wellesley College. She was also the recipient of a Fulbright Fellowship to study international relations at the Institut Universitaire de Hautes Etudes Internationales in Geneva, Switzerland.